UNSPSC 51283221: Spiramycin adipate

This classification denotes a macrolide antibiotic with the molecular formula C49H84N2O18, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L9KNT101OK, chemically known as hexanedioic acid, compd. with spiramycin (1:1), but more generally known as spiramycin adipate, which bears US NIH Compound Identifier 6450354. European Medicines Agency schedules spiramycin adipate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04526MIG.

Most nations, for tariff purposes, schedule spiramycin adipate under HS 29419000. SMILES:.

UNSPSC 51283221 Spiramycin adipate, a Commodity code, shows minimal relevant recent state and local procurement activity. The code nominally identifies a specific pharmaceutical ingredient, but the recent opportunities posted under this code do not involve spiramycin adipate itself; instead, they span naloxone procurement, direct-to-manufacturer prescription programs, general medical and first aid supplies, and multi-source generic pharmaceuticals. The mismatch between the code's narrow pharmaceutical scope and the actual buying activity suggests either a cataloging error in the state and local systems or a deliberate tagging decision that does not reflect the specific product named in the commodity definition.

The four recent opportunities—Seminole County's naloxone and drug deactivation systems IFB (response due July 26, 2023), Texas HHS Commission's RFI for direct-to-manufacturer prescription programs (April 3, 2026), City of Tampa's medical and first aid supplies IFB with a $700,000 estimated value and SLBE set-aside (response due March 13, 2026), and Minnesota MMCAP's RFP for generic pharmaceuticals and OTC products (response due March 26, 2026)—represent county health departments, state health agencies, municipal fire departments, and multi-state cooperative purchasing vehicles. None of these opportunities explicitly solicits spiramycin adipate or any spiramycin product. The geographic spread spans Florida, Texas, and Minnesota through the visible opportunities, with MMCAP's multi-state cooperative extending to Oregon. For firms pursuing work under this code, the disconnect between the code's nominal scope and actual buying patterns suggests the code is not a reliable filter for procurement activity in spiramycin or closely related pharmaceuticals; bidders should focus on the broader pharmaceutical-supply opportunities visible in the recent record rather than assuming this commodity code will generate targeted spiramycin solicitations.